Crystal structure of a staphylokinase variant - A model for reduced antigenicity

被引:8
作者
Chen, YH
Song, G
Jiang, F
Feng, L
Zhang, XX
Ding, Y
Bartlam, M
Yang, A
Ma, X
Ye, S
Liu, YW
Tang, H
Song, HY
Rao, ZH [1 ]
机构
[1] Tsing Hua Univ, Struct Biol Lab, Sch Life Sci & Engn, MOE Lab Prot Sci, Beijing 100084, Peoples R China
[2] Shanghai Med Univ, Dept Mol Genet, Shanghai, Peoples R China
来源
EUROPEAN JOURNAL OF BIOCHEMISTRY | 2002年 / 269卷 / 02期
关键词
staphylokinase; dimer; crystal structure; antigenicity; protein engineering;
D O I
10.1046/j.0014-2956.2001.02706.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Staphylokinase (SAK) is a 15.5-kDa protein from Staphylococcus aureus that activates plasminogen by forming a 1:1 complex with plasmin. Recombinant SAK has been shown in clinical trials to induce fibrin-specific clot lysis in patients with acute myocardial infarction. However, SAK elicits high titers of neutralizing antibodies. Biochemical and protein engineering studies have demonstrated the feasibility of generating SAK variants with reduced antigenicity yet intact thrombolytic potency. Here, we present X-ray crystallographic evidence that the SAK(S41G) mutant may assume a dimeric structure. This dimer model, at 2.3-Angstrom resolution, could explain a major antigenic epitope (residues A72-F76 and residues K135-K136) located in the vicinity of the dimer interface as identified by phage-display. These results suggest that SAK antigenicity may be reduced by eliminating dimer formation. We propose several potential mutation sites at the dimer interface that may further reduce the antigenicity of SAK.
引用
收藏
页码:705 / 711
页数:7
相关论文
共 36 条
  • [1] Abdelouahed M, 1997, THROMB HAEMOSTASIS, V77, P815
  • [2] BRUNNETT B, 1993, SURVEYS MATH IND, V3, P1
  • [3] Collen D, 1997, CIRCULATION, V95, P463
  • [4] Collen D, 1997, CIRCULATION, V95, P455
  • [5] MECHANISMS OF ACTIVATION OF MAMMALIAN PLASMA FIBRINOLYTIC SYSTEMS WITH STREPTOKINASE AND WITH RECOMBINANT STAPHYLOKINASE
    COLLEN, D
    VANHOEF, B
    SCHLOTT, B
    HARTMANN, M
    GUHRS, KH
    LIJNEN, HR
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1993, 216 (01): : 307 - 314
  • [6] Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent
    Collen, D
    [J]. NATURE MEDICINE, 1998, 4 (03) : 279 - 284
  • [7] Recombinant staphylokinase variants with altered immunoreactivity .1. Construction and characterization
    Collen, D
    Bernaerts, R
    Declerck, P
    DeCock, F
    Demarsin, E
    Jenne, S
    Laroche, Y
    Lijnen, HR
    Silence, K
    Verstreken, M
    [J]. CIRCULATION, 1996, 94 (02) : 197 - 206
  • [8] Collen D, 1995, Verh K Acad Geneeskd Belg, V57, P183
  • [9] Engineered staphylokinase variants with reduced immunogenicity
    Collen, D
    [J]. FIBRINOLYSIS & PROTEOLYSIS, 1998, 12 : 59 - 65
  • [10] COLLEN D, 1993, J BIOL CHEM, V268, P8284